Nasdaq · Healthcare
IDEXX LABORATORIES INC /DE (IDXX)
As-reported financials and recent SEC filings for IDEXX LABORATORIES INC /DE, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$4.30B
Net income
$1.06B
Net margin
24.6%
Diluted EPS
$13.08
ROE
66.0%
P/E (TTM)
41.3×
Market cap
$44.24B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B |
| Gross profit | $2.66B | $2.38B | $2.19B | $2.00B | $1.89B |
| Operating income | $1.36B | $1.13B | $1.10B | $898.8M | $932.0M |
| Net income | $1.06B | $887.9M | $845.0M | $679.1M | $744.8M |
| Diluted EPS | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-02
View on EDGAR →SD2026-06-01
View on EDGAR →1442026-05-20
View on EDGAR →8-K2026-05-15
View on EDGAR →42026-05-14
View on EDGAR →42026-05-14
View on EDGAR →42026-05-14
View on EDGAR →42026-05-14
View on EDGAR →Go deeper on IDXX
Search IDEXX LABORATORIES INC /DE’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.